News Releases

News Releases

Date Title
Jan 3, 2019 Sesen Bio Announces Positive Preliminary 12-Month Data from Registration Phase 3 VISTA Trial of Vicinium for Non-Muscle Invasive Bladder Cancer
Complete Response Rates from All Four Time Points in Carcinoma in Situ Patients In-line with Phase 2 Data Company to Host Conference Call Today, January 3 , at 8:30 a.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2019-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company advancing
Top